Cargando…

Genetic Variation of PD-L1 Gene Affects its Expression and Is Related to Clinical Outcome in Epithelial Ovarian Cancer

OBJECTIVE: This study aims to investigate the effect of polymorphisms of programmed cell death-ligand 1 (PD-L1) on the risk and patient’s outcomes of epithelial ovarian cancer (EOC). METHODS: Totally, 568 patients and 532 healthy women were included. Three polymorphisms in the PD-L1 gene, rs2297136,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Haiyan, Li, Yan, Si, Wengang, Hua, Tian, Chen, Juan, Kang, Shan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204247/ https://www.ncbi.nlm.nih.gov/pubmed/35719980 http://dx.doi.org/10.3389/fonc.2022.763134

Ejemplares similares

Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
por: Chardin, Laure, et al.
Publicado: (2021)

Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer
por: Buderath, Paul, et al.
Publicado: (2019)

Construction and Validation of a Platinum Sensitivity Predictive Model With Multiple Genomic Variations for Epithelial Ovarian Cancer
por: Zheng, Hong, et al.
Publicado: (2021)

Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade
por: Tian, Tian, et al.
Publicado: (2021)

The Expression of PD-L1 and B7-H4 in Thymic Epithelial Tumor and Its Relationship With Tumor Immune-Infiltrating Cells
por: Yan, Xiaotian, et al.
Publicado: (2021)

PD-L1 expression and association with genetic background in pheochromocytoma and paraganglioma
por: Hadrava Vanova, Katerina, et al.
Publicado: (2022)

Inferring Homologous Recombination Deficiency of Ovarian Cancer From the Landscape of Copy Number Variation at Subchromosomal and Genetic Resolutions
por: Zhang, Meng, et al.
Publicado: (2021)

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
por: Song, Joon Seon, et al.
Publicado: (2019)

PD-L1 Amino Acid Position 88 Represents a Hotspot for PD-L1 Stability With Relevance for PD-L1 Inhibition
por: Claaß, Luise Victoria, et al.
Publicado: (2022)

Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
por: Jiang, Yifan, et al.
Publicado: (2020)

CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma
por: Song, Yue, et al.
Publicado: (2020)

Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC
por: Lin, Weimin, et al.
Publicado: (2018)

The Association Between the Incidence Risk of Peripheral Neuropathy and PD-1/PD-L1 Inhibitors in the Treatment for Solid Tumor Patients: A Systematic Review and Meta-Analysis
por: Si, Zhihua, et al.
Publicado: (2019)

Epithelial–Mesenchymal Transition in Ovarian Carcinoma
por: Davidson, Ben, et al.
Publicado: (2012)

c-MYC and Epithelial Ovarian Cancer
por: Reyes-González, Jeyshka M., et al.
Publicado: (2021)

A Novel Sushi-IL15-PD1 CAR-NK92 Cell Line With Enhanced and PD-L1 Targeted Cytotoxicity Against Pancreatic Cancer Cells
por: Xu, Da-Lai, et al.
Publicado: (2022)

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
por: Bie, Fenglong, et al.
Publicado: (2022)

Corrigendum: CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma
por: Song, Yue, et al.
Publicado: (2021)

Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
por: Cheng, Chao, et al.
Publicado: (2022)

Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis
por: Huang, Ya-fang, et al.
Publicado: (2019)

PD-1/PD-L1 inhibitor treatment and its impact on clinical imaging in non-small cell lung cancer: a systematic review and meta-analysis of immune-related adverse events
por: Mohammed, Nader, et al.
Publicado: (2023)

Magnetic resonance imaging radiomics to differentiate ovarian sex cord-stromal tumors and primary epithelial ovarian cancers
por: Cheng, Meiying, et al.
Publicado: (2023)

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
por: Zhang, Yuedi, et al.
Publicado: (2022)

Role of EZH2 in Epithelial Ovarian Cancer: From Biological Insights to Therapeutic Target
por: Li, Hua, et al.
Publicado: (2013)

Tumor-specific T cell-mediated upregulation of PD-L1 in myelodysplastic syndrome cells does not affect T-cell killing
por: Ferrari, Valentina, et al.
Publicado: (2022)

Immunosuppression in Gliomas via PD-1/PD-L1 Axis and Adenosine Pathway
por: Scheffel, Thamiris Becker, et al.
Publicado: (2021)

The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy
por: Wen, Lu, et al.
Publicado: (2021)

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
por: Li, Zhitao, et al.
Publicado: (2021)

The Effect of Histological Subtypes on Outcomes of Stage IV Epithelial Ovarian Cancer
por: Zhou, Juan, et al.
Publicado: (2018)

ICSBP-induced PD-L1 enhances osteosarcoma cell growth
por: Sung, Jee Young, et al.
Publicado: (2022)

ITM2A as a Tumor Suppressor and Its Correlation With PD-L1 in Breast Cancer
por: Zhang, Rui, et al.
Publicado: (2021)

Targeted Glucose or Glutamine Metabolic Therapy Combined With PD-1/PD-L1 Checkpoint Blockade Immunotherapy for the Treatment of Tumors - Mechanisms and Strategies
por: Ma, Guofeng, et al.
Publicado: (2021)

Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer
por: Zhai, Xiaoyang, et al.
Publicado: (2020)

The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer
por: Yang, Hui, et al.
Publicado: (2020)

Tackling Immune Targets for Breast Cancer: Beyond PD-1/PD-L1 Axis
por: Tabana, Yasser, et al.
Publicado: (2021)

PD-1/PD-L1 Correlates With the Efficacy of the Treatment of Concurrent Chemoradiotherapy in Cervical Cancer
por: Zhang, Hanqun, et al.
Publicado: (2022)

Mutation Landscape of Homologous Recombination Repair Genes in Epithelial Ovarian Cancer in China and Its Relationship With Clinicopathlological Characteristics
por: Yao, Qianlan, et al.
Publicado: (2022)

Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV
por: Klausen, Uffe, et al.
Publicado: (2022)

Predictive effect of molecular and clinical characteristics for the OS and PFS efficacy of anti-PD-1/PD-L1 immunotherapy in patients with NSCLC: a meta-analysis and systematic review
por: An, Rui, et al.
Publicado: (2021)

Systematic Assessment of Risk of Fever in Solid Tumor Patients Treated With PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
por: Liu, Hongmei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hn1g72msu5pl9vrnfrvao9ge48